Ocular Therapeutix Inc (OCUL) Stock Analysis

Ocular Therapeutix Inc (OCUL) is a publicly traded company in the HEALTHCARE sector. It trades at $8.93, carries a market capitalization of $1.96B. This page summarizes the public market data, fundamentals, and frequently asked questions for OCUL, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Ocular Therapeutix Inc currently has a Neutral sentiment score of -0.04.

About Ocular Therapeutix Inc

Ocular Therapeutix, Inc. is a biopharmaceutical leader in the development and commercialization of groundbreaking therapies for ophthalmic diseases, utilizing its innovative bioresorbable hydrogel platform technology. Headquartered in Bedford, Massachusetts, the company is dedicated to meeting unmet medical needs in eye care through a robust pipeline of products designed to improve patient adherence and therapeutic effectiveness. With a strong emphasis on research and development, Ocular Ther...

GNG Research Analysis

GNG Research scores Ocular Therapeutix Inc (OCUL) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for OCUL.

Frequently Asked Questions

Does OCUL pay dividends?

Ocular Therapeutix Inc (OCUL) does not currently pay a regular dividend.

What is OCUL's market cap?

Ocular Therapeutix Inc (OCUL) has a market capitalization of $1.96B with a current stock price of $8.93.